Hologic Stock Price, News & Analysis (NASDAQ:HOLX)

$43.24 -0.22 (-0.51 %)
(As of 01/22/2018 04:00 PM ET)
Previous Close$43.24
Today's Range$42.83 - $43.60
52-Week Range$35.76 - $46.80
Volume2.73 million shs
Average Volume2.87 million shs
Market Capitalization$11.89 billion
P/E Ratio16.38
Dividend YieldN/A
Beta0.95

About Hologic (NASDAQ:HOLX)

Hologic logoHologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNASDAQ:HOLX
CUSIP43644010
Phone+1-508-2632900

Debt

Debt-to-Equity Ratio0.79%
Current Ratio0.79%
Quick Ratio0.61%

Price-To-Earnings

Trailing P/E Ratio16.3787878787879
Forward P/E Ratio20.02
P/E Growth2.06

Sales & Book Value

Annual Sales$3.06 billion
Price / Sales3.90
Cash Flow$3.65 per share
Price / Cash11.86
Book Value$9.93 per share
Price / Book4.35

Profitability

Trailing EPS$2.64
Net Income$755.50 million
Net Margins24.70%
Return on Equity21.69%
Return on Assets7.20%

Miscellaneous

Employees6,233
Outstanding Shares275,680,000

Hologic (NASDAQ:HOLX) Frequently Asked Questions

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) announced its quarterly earnings results on Wednesday, November, 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.49 by $0.01. The medical equipment provider earned $802.90 million during the quarter, compared to analyst estimates of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm's quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.52 EPS. View Hologic's Earnings History.

When will Hologic make its next earnings announcement?

Hologic is scheduled to release their next quarterly earnings announcement on Thursday, February, 8th 2018. View Earnings Estimates for Hologic.

What guidance has Hologic issued on next quarter's earnings?

Hologic updated its FY18 earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of $2.10-2.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.15. The company issued revenue guidance of $3.2-3.28 billion, compared to the consensus revenue estimate of $3.30 billion.Hologic also updated its Q1 guidance to $0.48-0.50 EPS.

Where is Hologic's stock going? Where will Hologic's stock price be in 2018?

14 analysts have issued 12-month target prices for Hologic's stock. Their forecasts range from $42.00 to $53.00. On average, they expect Hologic's share price to reach $48.79 in the next year. View Analyst Ratings for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

  • 1. Needham & Company LLC analysts commented, "FDA’s latest monthly Mammography Quality Standards Act (MQSA) statistics were published on 11/1/17. The number of digital breast tomosynthesis (DBT) units increased by 143 during October which represents a 5.1% Y/Y increase. DBT unit penetration increased to 29.0% from 28.5% last month and facility penetration increased to 44.0% from 42.8% last month. More importantly, DBT units placements were up 5.1% in 10/17 vs. 10/16. Based on this, we think that HOLX’s Breast Health business could see improved growth in F1Q18." (11/3/2017)
  • 2. According to Zacks Investment Research, "Hologic has been trading below the broader industry over the last six months. Moreover, the lowered guidance suggests dull prospects. Furthermore, the blood screening divestiture is expected to impede the company’s growth momentum in the days ahead. Foreign currency headwinds and a competitive landscape also continue to pose challenges. On a positive note, Hologic is optimistic about the recent commercial launch of the Brevera breast biopsy system in the United States. The company has been witnessing strength in the molecular diagnostics and GYN Surgical businesses. Moreover, sales are driven by the company’s recent receipt of CE mark for its new Panther Fusion system and Panther Fusion assays for flu and respiratory testing." (10/31/2017)

Are investors shorting Hologic?

Hologic saw a drop in short interest in December. As of December 15th, there was short interest totalling 8,373,389 shares, a drop of 25.1% from the November 30th total of 11,184,741 shares. Based on an average daily volume of 3,506,358 shares, the days-to-cover ratio is presently 2.4 days. Approximately 3.1% of the shares of the company are short sold.

Who are some of Hologic's key competitors?

Who are Hologic's key executives?

Hologic's management team includes the folowing people:

  • Stephen P. MacMillan, Chairman of the Board, President, Chief Executive Officer (Age 53)
  • Robert W. McMahon, Chief Financial Officer (Age 48)
  • Sanjay Prabhakaran, Regional President - Asia
  • Peter J. Valenti III, Division President- Breast and Skeletal Health (Age 53)
  • Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada
  • Thomas A. West, Division President- Diagnostics (Age 53)
  • Michael J. Watts, Vice President, IR Contact Officer
  • John M. Griffin, General Counsel (Age 56)
  • Elaine S. Ullian, Lead Independent Director (Age 69)
  • Charles J. Dockendorff, Director (Age 62)

Who owns Hologic stock?

Hologic's stock is owned by many different of retail and institutional investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.38%), Davis R M Inc. (0.29%), Gateway Investment Advisers LLC (0.19%), Bank of Montreal Can (0.12%), Eastern Bank (0.10%) and Chevy Chase Trust Holdings Inc. (0.09%). Company insiders that own Hologic stock include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

Who sold Hologic stock? Who is selling Hologic stock?

Hologic's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, DnB Asset Management AS, Davis R M Inc., Central Bank & Trust Co., Exxonmobil Investment Management Inc. TX, Chevy Chase Trust Holdings Inc., Gofen & Glossberg LLC IL and Whalerock Point Partners LLC. Company insiders that have sold Hologic company stock in the last year include Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Peter J Valenti III and Sally Crawford. View Insider Buying and Selling for Hologic.

Who bought Hologic stock? Who is buying Hologic stock?

Hologic's stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Gateway Investment Advisers LLC, Fox Run Management L.L.C., KAMES CAPITAL plc, State of Alaska Department of Revenue, LaFleur & Godfrey LLC, Eastern Bank and Creative Planning. View Insider Buying and Selling for Hologic.

How do I buy Hologic stock?

Shares of Hologic can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of Hologic stock can currently be purchased for approximately $43.24.

How big of a company is Hologic?

Hologic has a market capitalization of $11.89 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.64 on an earnings per share basis. Hologic employs 6,233 workers across the globe.

How can I contact Hologic?

Hologic's mailing address is 250 Campus Dr, MARLBOROUGH, MA 01752-3020, United States. The medical equipment provider can be reached via phone at +1-508-2632900 or via email at [email protected]


MarketBeat Community Rating for Hologic (HOLX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  568 (Vote Outperform)
Underperform Votes:  384 (Vote Underperform)
Total Votes:  952
MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hologic (NASDAQ:HOLX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.792.692.69
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $48.79$47.93$47.77$47.69
Price Target Upside: 11.26% upside10.21% upside29.49% upside5.03% upside

Hologic (NASDAQ:HOLX) Consensus Price Target History

Price Target History for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2018Deutsche BankDowngradeBuy -> Hold$49.00MediumView Rating Details
1/9/2018Needham & Company LLCReiterated RatingBuy -> Buy$48.00 -> $50.00LowView Rating Details
1/4/2018Bank of AmericaUpgradeNeutral -> Buy$50.00LowView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform -> Outperform$50.00MediumView Rating Details
12/20/2017CowenUpgradeBuy$52.00LowView Rating Details
12/8/2017Goldman Sachs GroupUpgradeBuy -> Conviction-Buy$45.00 -> $50.00LowView Rating Details
11/9/2017Piper Jaffray CompaniesReiterated RatingBuy$48.00N/AView Rating Details
10/10/2017Jefferies GroupReiterated RatingBuy$49.00 -> $44.00N/AView Rating Details
10/9/2017Stifel NicolausReiterated RatingBuy -> Buy$48.00 -> $45.00N/AView Rating Details
9/22/2017Royal Bank of CanadaReiterated RatingHold$42.00LowView Rating Details
8/9/2017BarclaysReiterated RatingEqual Weight$53.00 -> $51.00LowView Rating Details
5/14/2017BTIG ResearchReiterated RatingBuy$47.00LowView Rating Details
5/9/2017Canaccord GenuityReiterated RatingBuy$53.00LowView Rating Details
3/30/2017Leerink SwannReiterated RatingOutperform$52.00LowView Rating Details
7/28/2016Morgan StanleyBoost Price TargetEqual Weight$38.00 -> $40.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
1/28/2016JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Hologic (NASDAQ:HOLX) Earnings History and Estimates Chart

Earnings by Quarter for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ HOLX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/2018$0.50N/AView Earnings Details
11/8/2017Q4 2017$0.49$0.50$792.54 million$802.90 millionViewN/AView Earnings Details
8/2/2017Q3 2017$0.49$0.50$799.70 million$806.10 millionViewListenView Earnings Details
5/10/2017Q2 17$0.46$0.50$685.24 million$715.40 millionViewN/AView Earnings Details
2/1/2017Q117$0.51$0.52$725.01 million$734.40 millionViewListenView Earnings Details
11/2/2016Q416$0.50$0.52$721.52 million$726.80 millionViewN/AView Earnings Details
7/27/2016Q316$0.48$0.51$703.66 million$717.40 millionViewListenView Earnings Details
4/27/2016Q216$0.46$0.47$686.82 million$693.30 millionViewListenView Earnings Details
1/27/2016Q116$0.42$0.46$688.68 million$695.20 millionViewListenView Earnings Details
11/4/2015Q415$0.42$0.43$691.94 million$702.80 millionViewListenView Earnings Details
7/29/2015Q315$0.39$0.43$653.85 million$693.90 millionViewListenView Earnings Details
4/29/2015Q215$0.39$0.41$646.49 million$655.50 millionViewN/AView Earnings Details
1/28/2015Q115$0.36$0.39$630.79 million$652.80 millionViewListenView Earnings Details
11/5/2014Q414$0.37$0.43$636.20 million$660.60 millionViewListenView Earnings Details
7/30/2014Q314$0.34$0.37$621.89 million$632.60 millionViewListenView Earnings Details
4/30/2014Q214$0.33$0.37$609.35 million$625.00 millionViewListenView Earnings Details
2/3/2014Q114$0.31$0.34$609.65 million$612.40 millionViewListenView Earnings Details
11/11/2013Q413$0.37$0.39$624.40 million$622.10 millionViewListenView Earnings Details
8/5/2013Q3 2013$0.37$0.38$627.05 million$626.10 millionViewListenView Earnings Details
5/6/2013Q2 2013$0.34$0.35$639.53 million$619.10 millionViewListenView Earnings Details
2/4/2013Q1 2013$0.37$0.38$646.52 million$644.60 millionViewListenView Earnings Details
11/12/2012Q412$0.36$0.37$581.12 million$600.20 millionViewN/AView Earnings Details
7/30/2012$0.34$0.35ViewN/AView Earnings Details
4/30/2012$0.33$0.33ViewN/AView Earnings Details
1/30/2012$0.32$0.34ViewN/AView Earnings Details
11/7/2011$0.33$0.34ViewN/AView Earnings Details
8/1/2011$0.32$0.32ViewN/AView Earnings Details
5/2/2011$0.28$0.30ViewN/AView Earnings Details
1/31/2011$0.28$0.30ViewN/AView Earnings Details
11/8/2010Q4 2010$0.30$0.30ViewN/AView Earnings Details
8/2/2010Q3 2010$0.29$0.30ViewN/AView Earnings Details
5/3/2010Q2 2010$0.29$0.29ViewN/AView Earnings Details
2/1/2010Q1 2010$0.26$0.29ViewN/AView Earnings Details
11/9/2009Q4 2009$0.26$0.28ViewN/AView Earnings Details
8/3/2009Q3 2009$0.26$0.29ViewN/AView Earnings Details
5/4/2009Q2 2009$0.27$0.29ViewN/AView Earnings Details
2/2/2009Q1 2009$0.30$0.31ViewN/AView Earnings Details
11/11/2008Q4 2008$0.30$0.30ViewN/AView Earnings Details
7/30/2008Q3 2008$0.29$0.33ViewN/AView Earnings Details
5/1/2008Q2 2008$0.28$0.29ViewN/AView Earnings Details
1/31/2008Q1 2008$0.23$0.25ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Hologic (NASDAQ:HOLX) Earnings Estimates

2018 EPS Consensus Estimate: $2.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.49$0.52$0.50
Q2 20183$0.51$0.52$0.52
Q3 20183$0.54$0.57$0.55
Q4 20183$0.53$0.58$0.55
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Hologic (NASDAQ:HOLX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Hologic (NASDAQ HOLX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 97.24%
Insider Trades by Quarter for Hologic (NASDAQ:HOLX)
Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ HOLX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2017Karleen Marie ObertonVPSell1,023$39.84$40,756.32View SEC Filing  
11/13/2017Elaine UllianDirectorSell9,282$40.50$375,921.00View SEC Filing  
11/8/2017Karleen Marie ObertonVPSell1,256$39.29$49,348.249,406View SEC Filing  
11/6/2017Karleen Marie ObertonVPSell538$39.40$21,197.208,343View SEC Filing  
10/10/2017Lawrence M LevyDirectorSell9,596$36.81$353,228.76View SEC Filing  
10/9/2017Lawrence M LevyDirectorSell7,138$37.38$266,818.44View SEC Filing  
9/7/2017Lawrence M. LevyDirectorSell7,139$39.04$278,706.56View SEC Filing  
8/3/2017Elaine UllianDirectorSell6,902$40.12$276,908.2423,810View SEC Filing  
7/17/2017Karleen Marie ObertonVPSell4,704$45.19$212,573.76View SEC Filing  
7/3/2017Elaine UllianDirectorSell8,849$45.28$400,682.7223,810View SEC Filing  
6/7/2017Lawrence M LevyDirectorSell2,960$44.54$131,838.4045,634View SEC Filing  
6/2/2017Elaine UllianDirectorSell8,938$43.99$393,182.6223,810View SEC Filing  
5/30/2017Peter J Valenti IIIInsiderSell10,005$43.44$434,617.2020,994View SEC Filing  
5/24/2017Lawrence M LevyDirectorSell9,193$42.93$394,655.4946,206View SEC Filing  
5/17/2017Lawrence M LevyDirectorSell9,076$42.80$388,452.8043,165View SEC Filing  
5/10/2017Lawrence M LevyDirectorSell9,837$45.34$446,009.5840,577View SEC Filing  
5/3/2017Lawrence M LevyDirectorSell10,203$45.00$459,135.0038,832View SEC Filing  
4/26/2017Lawrence M LevyDirectorSell10,374$44.46$461,228.0437,377View SEC Filing  
4/24/2017Sally CrawfordDirectorSell16,969$44.00$746,636.00157,305View SEC Filing  
4/19/2017Lawrence M LevyDirectorSell10,836$42.49$460,421.6425,839View SEC Filing  
4/12/2017Lawrence M LevyDirectorSell10,757$42.45$456,634.6524,596View SEC Filing  
4/3/2017Elaine UllianDirectorSell9,104$42.40$386,009.6023,810View SEC Filing  
3/8/2017Sally CrawfordDirectorSell17,396$42.00$730,632.00152,305View SEC Filing  
2/3/2017Elaine UllianDirectorSell9,423$39.54$372,585.4236,798View SEC Filing  
11/21/2016Karleen Marie ObertonVPSell3,023$38.32$115,841.3613,260View SEC Filing  
11/15/2016Karleen Marie ObertonVPSell1,211$36.55$44,262.0510,859View SEC Filing  
11/8/2016Karleen Marie ObertonVPSell984$38.57$37,952.889,065View SEC Filing  
11/7/2016Karleen Marie ObertonVPSell522$38.53$20,112.669,839View SEC Filing  
10/10/2016Elaine UllianDirectorSell18,236$39.88$727,251.6842,898View SEC Filing  
10/10/2016Karleen Marie ObertonVPSell31,470$40.00$1,258,800.0017,005View SEC Filing  
7/21/2016Nancy LeamingDirectorSell8,179$37.00$302,623.0067,140View SEC Filing  
7/11/2016Nancy LeamingDirectorSell6,221$36.04$224,204.8455,053View SEC Filing  
6/1/2016Lawrence M LevyDirectorSell17,794$34.41$612,291.5423,257View SEC Filing  
5/27/2016Peter J Valenti IIIInsiderSell10,022$33.83$339,044.269,023View SEC Filing  
5/26/2016Elaine UllianDirectorSell6,896$33.85$233,429.6031,157View SEC Filing  
5/26/2016Karleen Marie ObertonVPSell4,228$33.85$143,117.808,819View SEC Filing  
2/24/2016David R Lavance JrDirectorSell11,621$34.50$400,924.5020,983View SEC Filing  
11/10/2015Lawrence M. LevyDirectorSell20,000$40.70$814,000.003,914View SEC Filing  
9/21/2015Lawrence M. LevyDirectorSell5,000$42.02$210,100.003,914View SEC Filing  
9/8/2015Wayne WilsonDirectorSell100,000$39.00$3,900,000.0039,215View SEC Filing  
8/28/2015Wayne WilsonDirectorSell11,146$39.70$442,496.2039,215View SEC Filing  
8/26/2015Wayne WilsonDirectorSell25,080$38.61$968,338.8039,215View SEC Filing  
8/14/2015Wayne WilsonDirectorSell13,257$42.20$559,445.40View SEC Filing  
6/3/2015Lawrence M LevyDirectorSell10,000$36.45$364,500.00View SEC Filing  
5/22/2015Lawrence M LevyDirectorSell5,000$35.05$175,250.00View SEC Filing  
5/4/2015Lawrence M LevyDirectorSell10,000$34.36$343,600.00View SEC Filing  
3/6/2015David R Lavance JrDirectorSell12,000$32.12$385,440.00View SEC Filing  
2/13/2015David R Lavance JrDirectorSell8,000$30.32$242,560.00View SEC Filing  
1/29/2015Karleen Marie ObertonVPSell18,997$30.00$569,910.00View SEC Filing  
11/11/2014Karleen Marie ObertonVPSell2,609$26.30$68,616.70View SEC Filing  
11/3/2014Karleen Marie ObertonVPSell12,507$26.83$335,562.81View SEC Filing  
10/31/2014Roger D MillsSVPSell14,506$26.00$377,156.00View SEC Filing  
9/9/2014Elaine UllianDirectorBuy7,900$25.36$200,344.00View SEC Filing  
5/9/2014Rohan HastieSVPSell6,037$24.36$147,061.321,500View SEC Filing  
5/8/2014Glenn MuirCFOSell50,000$24.26$1,213,000.00815,306View SEC Filing  
5/6/2014Glenn MuirCFOSell196,000$23.29$4,564,840.00815,306View SEC Filing  
5/6/2014Lawrence LevyDirectorSell5,052$23.58$119,126.16View SEC Filing  
5/6/2014Robert LavalleeCAOSell22,796$23.58$537,529.6811,341View SEC Filing  
3/14/2014David Lavance, Jr.DirectorSell5,500$21.49$118,195.00122View SEC Filing  
3/14/2014Glenn MuirCFOSell160,000$21.51$3,441,600.00815,306View SEC Filing  
3/7/2014Mark CaseyCAOSell3,251$22.53$73,245.0314,470View SEC Filing  
2/11/2014Stephen MacmillanCEOBuy38,600$21.58$832,988.00237,500View SEC Filing  
2/7/2014Stephen MacmillanCEOBuy198,900$20.78$4,133,142.00198,900View SEC Filing  
12/13/2013Robert LavalleeCAOSell15,677$21.70$340,190.9011,341View SEC Filing  
10/30/2013Glenn P MuirCFOSell140,000$22.32$3,124,800.00View SEC Filing  
10/15/2013Glenn P MuirCFOSell28,000$22.12$619,360.00View SEC Filing  
9/16/2013Glenn MuirCFOSell28,000$20.45$572,600.00825,891View SEC Filing  
9/13/2013Robert LavalleeCAOSell2,500$20.33$50,825.0019,090View SEC Filing  
8/20/2013David BradySVPSell42,328$22.80$965,078.4027,749View SEC Filing  
8/15/2013Glenn MuirCFOSell28,000$22.49$629,720.00825,891View SEC Filing  
8/8/2013Lawrence LevyDirectorSell5,000$22.50$112,500.005,052View SEC Filing  
8/8/2013Mark CaseyCAOSell14,804$22.57$334,126.2820,632View SEC Filing  
7/19/2013Robert H LavalleeCAOSell11,254$20.89$235,096.06View SEC Filing  
7/15/2013Glenn P MuirCFOSell28,000$19.78$553,840.00View SEC Filing  
7/1/2013Robert CascellaCEOSell20,000$19.55$391,000.00View SEC Filing  
6/17/2013Glenn P MuirCFOSell28,000$21.42$599,760.00View SEC Filing  
6/3/2013Robert CascellaCEOSell20,000$20.71$414,200.00View SEC Filing  
2/25/2013Lawrence M LevyDirectorSell5,000$22.00$110,000.00View SEC Filing  
9/5/2012Glenn P MuirCFOSell68,750$19.96$1,372,250.00View SEC Filing  
8/8/2012Glenn P MuirCFOSell68,750$19.69$1,353,687.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Hologic (NASDAQ HOLX) News Headlines

Source:
DateHeadline
Hologics Cynosure Division Launches TempSure™ EnviHologic's Cynosure Division Launches TempSure™ Envi
finance.yahoo.com - January 22 at 12:46 PM
Hologic launches new RF device for aesthetic useHologic launches new RF device for aesthetic use
seekingalpha.com - January 22 at 11:18 AM
Hologic (HOLX) Lowered to Hold at Deutsche BankHologic (HOLX) Lowered to Hold at Deutsche Bank
www.americanbankingnews.com - January 20 at 10:26 PM
Deutsche Bank Downgrades Hologic, Says Core Businesses Face Structural ChallengesDeutsche Bank Downgrades Hologic, Says Core Businesses Face Structural Challenges
www.msn.com - January 19 at 12:30 PM
Hologic, Inc. -- Moodys assigns Ba3 rating to Hologics senior unsecured bondsHologic, Inc. -- Moody's assigns Ba3 rating to Hologic's senior unsecured bonds
finance.yahoo.com - January 17 at 11:26 AM
Hologic Announces Pricing of Offering of $1 Billion of Senior NotesHologic Announces Pricing of Offering of $1 Billion of Senior Notes
www.prnewswire.com - January 16 at 10:19 PM
Hologic (HOLX) to Offer $1B of Senior NotesHologic (HOLX) to Offer $1B of Senior Notes
www.streetinsider.com - January 16 at 3:29 PM
Hologic Announces Offering of $1 Billion of Senior NotesHologic Announces Offering of $1 Billion of Senior Notes
finance.yahoo.com - January 16 at 3:29 PM
Hologic (HOLX) to Offer $1B of Senior Notes - StreetInsider.comHologic (HOLX) to Offer $1B of Senior Notes - StreetInsider.com
www.streetinsider.com - January 16 at 11:30 AM
Hologic, Inc. (HOLX) Given Consensus Recommendation of "Buy" by BrokeragesHologic, Inc. (HOLX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 16 at 8:00 AM
Hologic (HOLX) Lowered to "Sell" at BidaskClubHologic (HOLX) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - January 13 at 4:52 PM
Hologic (HOLX) Appoints Namal Nawana to BoardHologic (HOLX) Appoints Namal Nawana to Board
www.streetinsider.com - January 13 at 10:59 AM
Namal Nawana Elected to Hologic Board of DirectorsNamal Nawana Elected to Hologic Board of Directors
finance.yahoo.com - January 12 at 10:53 AM
Gabelli Weighs in on Hologic, Inc.s FY2018 Earnings (HOLX)Gabelli Weighs in on Hologic, Inc.'s FY2018 Earnings (HOLX)
www.americanbankingnews.com - January 11 at 3:58 PM
Contrasting Hologic (HOLX) and Illumina (ILMN)Contrasting Hologic (HOLX) and Illumina (ILMN)
www.americanbankingnews.com - January 11 at 3:06 AM
Hologic Sees Q1 Revenue Above Guidance RangeHologic Sees Q1 Revenue Above Guidance Range
www.finanznachrichten.de - January 9 at 3:31 PM
Hologic (HOLX) Reports Prelim. 1Q18 Revenue Above Consensus - StreetInsider.comHologic (HOLX) Reports Prelim. 1Q18 Revenue Above Consensus - StreetInsider.com
www.streetinsider.com - January 9 at 11:10 AM
Hologic (HOLX) Price Target Raised to $50.00Hologic (HOLX) Price Target Raised to $50.00
www.americanbankingnews.com - January 9 at 9:44 AM
Hologic to Announce Financial Results for the First Quarter of Fiscal 2018 on Thursday, February 8, 2018Hologic to Announce Financial Results for the First Quarter of Fiscal 2018 on Thursday, February 8, 2018
finance.yahoo.com - January 8 at 11:00 AM
Hologic Preliminary Revenues Increase 8% to Approximately $791 Million in the First Quarter of Fiscal 2018Hologic Preliminary Revenues Increase 8% to Approximately $791 Million in the First Quarter of Fiscal 2018
finance.yahoo.com - January 8 at 11:00 AM
 Brokerages Anticipate Hologic, Inc. (HOLX) Will Announce Quarterly Sales of $781.53 Million Brokerages Anticipate Hologic, Inc. (HOLX) Will Announce Quarterly Sales of $781.53 Million
www.americanbankingnews.com - January 8 at 8:38 AM
Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2042 are Eligible to ConvertHologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2042 are Eligible to Convert
finance.yahoo.com - January 5 at 10:27 AM
Should You Be Tempted To Buy Hologic Inc (NASDAQ:HOLX) At Its Current PE Ratio?Should You Be Tempted To Buy Hologic Inc (NASDAQ:HOLX) At Its Current PE Ratio?
finance.yahoo.com - January 4 at 10:58 AM
Hologic to Present at the 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)Hologic to Present at the 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - January 3 at 3:30 PM
Hologic to Present at the 36th Annual J.P. Morgan Healthcare ConferenceHologic to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 8:42 PM
Short Interest in Hologic, Inc. (HOLX) Decreases By 25.1%Short Interest in Hologic, Inc. (HOLX) Decreases By 25.1%
www.americanbankingnews.com - December 30 at 2:34 AM
ETFs with exposure to Hologic, Inc. : December 29, 2017ETFs with exposure to Hologic, Inc. : December 29, 2017
finance.yahoo.com - December 29 at 3:30 PM
Hologic, Inc. :HOLX-US: Earnings Analysis: Q4, 2017 By the Numbers : December 27, 2017Hologic, Inc. :HOLX-US: Earnings Analysis: Q4, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 1:28 PM
Hologic, Inc. (HOLX) Expected to Announce Quarterly Sales of $781.53 MillionHologic, Inc. (HOLX) Expected to Announce Quarterly Sales of $781.53 Million
www.americanbankingnews.com - December 23 at 8:30 AM
Hologic: The Med-Tech Company To Choose For Sustainable ... - Seeking AlphaHologic: The Med-Tech Company To Choose For Sustainable ... - Seeking Alpha
seekingalpha.com - December 22 at 9:00 PM
Free Post Earnings Research Report: Hologic’s Revenue Grew 10.5%Free Post Earnings Research Report: Hologic’s Revenue Grew 10.5%
finance.yahoo.com - December 22 at 10:28 AM
 Analysts Anticipate Hologic, Inc. (HOLX) to Post $0.49 Earnings Per Share Analysts Anticipate Hologic, Inc. (HOLX) to Post $0.49 Earnings Per Share
www.americanbankingnews.com - December 21 at 11:24 AM
Hologic (HOLX) Rating Increased to Buy at CowenHologic (HOLX) Rating Increased to Buy at Cowen
www.americanbankingnews.com - December 20 at 1:34 PM
ETFs with exposure to Hologic, Inc. : December 18, 2017ETFs with exposure to Hologic, Inc. : December 18, 2017
finance.yahoo.com - December 19 at 10:24 AM
Cowen: Hologic Is A Relatively Cheap Stock Overdue For UpsideCowen: Hologic Is A Relatively Cheap Stock Overdue For Upside
finance.yahoo.com - December 11 at 3:29 PM
Hologic (HOLX) Stock Rating Upgraded by CowenHologic (HOLX) Stock Rating Upgraded by Cowen
www.americanbankingnews.com - December 11 at 8:30 AM
Hologic: Meet Goldman Sachs New Conviction Buy - BenzingaHologic: Meet Goldman Sach's New 'Conviction Buy' - Benzinga
www.benzinga.com - December 9 at 3:31 PM
Six Off the Beaten Path Healthcare Stock GemsSix Off the Beaten Path Healthcare Stock Gems
finance.yahoo.com - December 9 at 3:31 PM
ETFs with exposure to Hologic, Inc. : December 8, 2017ETFs with exposure to Hologic, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 3:30 PM
Hologic: Meet Goldman Sachs New Conviction BuyHologic: Meet Goldman Sach's New 'Conviction Buy'
finance.yahoo.com - December 8 at 3:30 PM
Hologic (HOLX) Upgraded to "Conviction-Buy" by Goldman Sachs GroupHologic (HOLX) Upgraded to "Conviction-Buy" by Goldman Sachs Group
www.americanbankingnews.com - December 8 at 10:02 AM
Hologic Banks on Molecular Diagnostics, Competition Rife - NasdaqHologic Banks on Molecular Diagnostics, Competition Rife - Nasdaq
www.nasdaq.com - December 7 at 3:34 PM
Hologics Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA Nod - NasdaqHologic's Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA Nod - Nasdaq
www.nasdaq.com - December 7 at 3:34 PM
Hologic (HOLX) Receives 510(k) Clearance from FDA for its Panther Fusion AdV/hMPV/RV Assay - StreetInsider.comHologic (HOLX) Receives 510(k) Clearance from FDA for its Panther Fusion AdV/hMPV/RV Assay - StreetInsider.com
www.streetinsider.com - December 7 at 3:34 PM
Hologics Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA NodHologic's Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA Nod
finance.yahoo.com - December 7 at 10:04 AM
Hologic's Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA NodHologic's Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA Nod
finance.yahoo.com - December 7 at 10:04 AM
Hologic (HOLX) Receives 510(k) Clearance from FDA for its Panther Fusion AdV/hMPV/RV AssayHologic (HOLX) Receives 510(k) Clearance from FDA for its Panther Fusion AdV/hMPV/RV Assay
www.streetinsider.com - December 6 at 10:55 AM
Third Respiratory Assay Now FDA Cleared on Hologics New Panther Fusion® SystemThird Respiratory Assay Now FDA Cleared on Hologic's New Panther Fusion® System
finance.yahoo.com - December 6 at 10:54 AM
Needham & Company LLC Boosts Hologic (HOLX) Price Target to $48.00Needham & Company LLC Boosts Hologic (HOLX) Price Target to $48.00
www.americanbankingnews.com - December 5 at 12:38 PM
$782.88 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter$782.88 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter
www.americanbankingnews.com - December 5 at 5:50 AM

SEC Filings

Hologic (NASDAQ:HOLX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Hologic (NASDAQ:HOLX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Hologic (NASDAQ HOLX) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.